Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

MIR4435-2HG: A Tumor-associated Long Non-coding RNA

Author(s): Fangnan Zhao, Yuling Liu, Fangshun Tan, Lu Tang, Zhuoying Du, Jie Mou, Gang Zhou* and Chengfu Yuan*

Volume 28, Issue 25, 2022

Published on: 27 July, 2022

Page: [2043 - 2051] Pages: 9

DOI: 10.2174/1381612828666220607100228

Price: $65

conference banner
Abstract

Background: It is well known that the changes in the expression level of LncRNA can affect the progression of tumors, which has caused a great upsurge of research in recent years. Several LncRNAs have been identified to affect a series of cancers and can promote tumor growth, migration, and invasion. In this review, we aim to clarify the pathophysiological functions of LncRNA MIR4435-2 HG in multiple tumors.

Methods: By searching the literature through PubMed, this paper summarizes the relationship between MIR4435-2HG and tumor and its role in the occurrence and development of cancer and also explains the specific molecular mechanism of the effect of MIR4435-2HG on cancer.

Results: MIR4435-2HG can function as an oncogene in a variety of cancers. The expression level was reported to be abnormally elevated in a series of cancers, consisting of melanoma, gastric cancer, head and neck squamous cell carcinoma, oral squamous cell carcinoma, lung cancer, cervical cancer, prostate carcinoma, ovarian cancer, breast cancer, hepatocellular carcinoma, clear cell renal cell carcinoma malignant, glioma, and colorectal cancer. Moreover, MIR4435-2HG is related to the poor prognosis of a variety of cancers. MIR4435-2HG can also affect tumor proliferation, invasion, and apoptosis. In addition, MIR4435-2HG can also enhance the metabolic function of myeloid dendritic cells of elite HIV-1 controllers.

Conclusion: MIR4435-2HG affects the development of a variety of cancers. It can act as a clinical marker for early tumor diagnosis and affects tumor-targeted therapy.

Keywords: LncRNA, MIR4435-2HG, tumor, biomarkers, therapeutic target, diagnosis.

« Previous Next »
[1]
Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol 2021; 220(2): 220.
[http://dx.doi.org/10.1083/jcb.202009045] [PMID: 33464299]
[2]
Shen MY, Zhou GR, Zhang ZY. LncRNA MIR4435-2HG contributes into colorectal cancer development and predicts poor prognosis. Eur Rev Med Pharmacol Sci 2020; 24(4): 1771-7.
[PMID: 32141545]
[3]
Yang Z, Jiang S, Shang J, et al. LncRNA: Shedding light on mechanisms and opportunities in fibrosis and aging. Ageing Res Rev 2019; 52: 17-31.
[http://dx.doi.org/10.1016/j.arr.2019.04.001] [PMID: 30954650]
[4]
Guo X, Zhang Y, Liu L, Yang W, Zhang Q. HNF1A-AS1 regulates cell migration, invasion and glycolysis via modulating miR-124/MYO6 in colorectal cancer cells. OncoTargets Ther 2020; 13: 1507-18.
[http://dx.doi.org/10.2147/OTT.S231249] [PMID: 32110048]
[5]
Wang Y, Yang L, Chen T, et al. A novel lncRNA MCM3AP-AS1 promotes the growth of hepatocellular carcinoma by targeting miR-194-5p/FOXA1 axis. Mol Cancer 2019; 18: 28.
[6]
Teng F, Zhang JX, Chang QM, et al. LncRNA MYLK-AS1 facilitates tumor progression and angiogenesis by targeting miR-424-5p/E2F7 axis and activating VEGFR-2 signaling pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 2020; 39(1): 235.
[http://dx.doi.org/10.1186/s13046-020-01739-z] [PMID: 33168027]
[7]
Zhang P, Cao P, Zhu X, et al. Upregulation of long non-coding RNA HOXA-AS2 promotes proliferation and induces epithelial-mesenchymal transition in gallbladder carcinoma. Oncotarget 2017; 8(20): 33137-43.
[http://dx.doi.org/10.18632/oncotarget.16561] [PMID: 28388535]
[8]
Yang X, Song JH, Cheng Y, et al. Long non-coding RNA HNF1A-AS1 regulates proliferation and migration in oesophageal adenocarcinoma cells. Gut 2014; 63(6): 881-90.
[http://dx.doi.org/10.1136/gutjnl-2013-305266] [PMID: 24000294]
[9]
Chen D, Tang P, Wang Y, et al. Downregulation of long non-coding RNA MR4435-2HG suppresses breast cancer progression via the Wnt/β-catenin signaling pathway. Oncol Lett 2021; 21(5): 373.
[http://dx.doi.org/10.3892/ol.2021.12634] [PMID: 33777197]
[10]
Shen X, Ding Y, Lu F, Yuan H. Long noncoding RNA MIR4435-2HG promotes hepatocellular carcinoma proliferation and metastasis through the miR-22-3p/YWHAZ axis. 2020; 12: 6381-94.
[11]
Smyth EC, Nilsson M, Grabsch HI, van Grieken NCT, Lordick F. Gastric cancer. Lancet 2020; 396(10251): 635-48.
[http://dx.doi.org/10.1016/S0140-6736(20)31288-5] [PMID: 32861308]
[12]
Wang H, Wu M, Lu Y, et al. LncRNA MIR4435-2HG targets desmoplakin and promotes growth and metastasis of gastric cancer by activating Wnt/β-catenin signaling. Aging 2019; 11(17): 6657-73.
[http://dx.doi.org/10.18632/aging.102164] [PMID: 31484163]
[13]
Ke D, Li H, Zhang Y, et al. The combination of circulating long noncoding RNAs AK001058, INHBA-AS1, MIR4435-2HG, and CEBPA-AS1 fragments in plasma serve as diagnostic markers for gastric cancer. Oncotarget 2017; 8(13): 21516-25.
[http://dx.doi.org/10.18632/oncotarget.15628] [PMID: 28423525]
[14]
Miao Y, Sui J, Xu SY, Liang GY, Pu YP, Yin LH. Comprehensive analysis of a novel four-lncRNA signature as a prognostic biomarker for human gastric cancer. Oncotarget 2017; 8(43): 75007-24.
[http://dx.doi.org/10.18632/oncotarget.20496] [PMID: 29088841]
[15]
Pirker R. Conquering lung cancer: Current status and prospects for the future. Pulmonology 2020; 26(5): 283-90.
[http://dx.doi.org/10.1016/j.pulmoe.2020.02.005] [PMID: 32199906]
[16]
Qian H, Chen L, Huang J, et al. The lncRNA MIR4435-2HG promotes lung cancer progression by activating β-catenin signalling. J Mol Med 2018; 96(8): 753-64.
[http://dx.doi.org/10.1007/s00109-018-1654-5] [PMID: 29872866]
[17]
Yang M, He X, Huang X, Wang J, He Y, Wei L. LncRNA MIR4435-2HG-mediated upregulation of TGF-β1 promotes migration and proliferation of nonsmall cell lung cancer cells. Environ Toxicol 2020; 35(5): 582-90.
[http://dx.doi.org/10.1002/tox.22893] [PMID: 31875359]
[18]
Simiczyjew A, Dratkiewicz E, Mazurkiewicz J, Ziętek M, Matkowski R, Nowak D. The influence of tumor microenvironment on immune escape of melanoma. Int J Mol Sci 2020; 21(21): 21.
[http://dx.doi.org/10.3390/ijms21218359] [PMID: 33171792]
[19]
Kibbi N, Kluger H, Choi JN. Melanoma: Clinical presentations. Cancer Treat Res 2016; 167: 107-29.
[http://dx.doi.org/10.1007/978-3-319-22539-5_4] [PMID: 26601860]
[20]
Ma DM, Sun D, Wang J, Jin DH, Li Y, Han YE. Long non-coding RNA MIR4435-2HG recruits miR-802 from FLOT2 to promote melanoma progression. Eur Rev Med Pharmacol Sci 2020; 24(5): 2616-24.
[PMID: 32196611]
[21]
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers 2020; 6(1): 92.
[http://dx.doi.org/10.1038/s41572-020-00224-3] [PMID: 33243986]
[22]
Sun X, Zhang L, Liu S. The immune infiltration in HNSCC and its clinical value: A comprehensive study based on the TCGA and GEO databases. Comput Math Methods Med 2021; 2021: 1163250.
[http://dx.doi.org/10.1155/2021/1163250] [PMID: 34790249]
[23]
Wang S, Chen X, Qiao T. Long non-coding RNA MIR4435-2HG promotes the progression of head and neck squamous cell carcinoma by regulating the miR-383-5p/RBM3 axis. Oncol Rep 2021; 45(6): 45.
[http://dx.doi.org/10.3892/or.2021.8050] [PMID: 33846802]
[24]
Vitório JG, Duarte-Andrade FF, Dos Santos Fontes Pereira T, et al. Metabolic landscape of oral squamous cell carcinoma. Metabolomics 2020; 16(10): 105.
[http://dx.doi.org/10.1007/s11306-020-01727-6] [PMID: 33000429]
[25]
Shen H, Sun B, Yang Y, et al. MIR4435-2HG regulates cancer cell behaviors in oral squamous cell carcinoma cell growth by upregulating TGF-β1. Odontology 2020; 108(4): 553-9.
[http://dx.doi.org/10.1007/s10266-020-00488-x] [PMID: 32016787]
[26]
Zhang S, Li C, Liu J, et al. Fusobacterium nucleatum promotes epithelial-mesenchymal transiton through regulation of the lncRNA MIR4435-2HG/miR-296-5p/Akt2/SNAI1 signaling pathway. FEBS J 2020; 287(18): 4032-47.
[http://dx.doi.org/10.1111/febs.15233] [PMID: 31997506]
[27]
Revathidevi S, Murugan AK, Nakaoka H, Inoue I, Munirajan AK. APOBEC: A molecular driver in cervical cancer pathogenesis. Cancer Lett 2021; 496: 104-16.
[http://dx.doi.org/10.1016/j.canlet.2020.10.004] [PMID: 33038491]
[28]
Wang R, Liu L, Jiao J, Gao D. Knockdown of MIR4435-2HG suppresses the proliferation, migration and invasion of cervical cancer cells via regulating the miR-128-3p/MSI2 axis in vitro. Cancer Manag Res 2020; 12: 8745-56.
[http://dx.doi.org/10.2147/CMAR.S265545] [PMID: 33061572]
[29]
Xing P, Wang Y, Zhang L, Ma C, Lu J. Knockdown of lncRNA MIR4435-2HG and ST8SIA1 expression inhibits the proliferation, invasion and migration of prostate cancer cells in vitro and in vivo by blocking the activation of the FAK/AKT/β-catenin signaling pathway. Int J Mol Med 2021; 47(6): 47.
[http://dx.doi.org/10.3892/ijmm.2021.4926] [PMID: 33846784]
[30]
Zhang H, Meng H, Huang X, et al. lncRNA MIR4435-2HG promotes cancer cell migration and invasion in prostate carcinoma by upregulating TGF-β1. Oncol Lett 2019; 18(4): 4016-21.
[http://dx.doi.org/10.3892/ol.2019.10757] [PMID: 31516603]
[31]
Zhu L, Wang A, Gao M, Duan X, Li Z. LncRNA MIR4435-2HG triggers ovarian cancer progression by regulating miR-128-3p/CKD14 axis. Cancer Cell Int 2020; 20: 145.
[http://dx.doi.org/10.1186/s12935-020-01227-6] [PMID: 32377170]
[32]
Gong J, Xu X, Zhang X, Zhou Y. LncRNA MIR4435-2HG is a potential early diagnostic marker for ovarian carcinoma. Acta Biochim Biophys Sin 2019; 51(9): 953-9.
[http://dx.doi.org/10.1093/abbs/gmz085] [PMID: 31435668]
[33]
Wang B, Tang D, Zhang Z, Wang Z. Identification of aberrantly expressed lncRNA and the associated TF-mRNA network in hepatocellular carcinoma. J Cell Biochem 2020; 121(2): 1491-503.
[http://dx.doi.org/10.1002/jcb.29384] [PMID: 31498488]
[34]
Bai Y, Lin H, Chen J, Wu Y, Yu S. Identification of prognostic glycolysis-related lncrna signature in tumor immune microenvironment of hepatocellular carcinoma. Front Mol Biosci 2021; 8: 645084.
[http://dx.doi.org/10.3389/fmolb.2021.645084] [PMID: 33968985]
[35]
Kong Q, Liang C, Jin Y, et al. The lncRNA MIR4435-2HG is upregulated in hepatocellular carcinoma and promotes cancer cell proliferation by upregulating miRNA-487a. Cell Mol Biol Lett 2019; 24: 26.
[http://dx.doi.org/10.1186/s11658-019-0148-y] [PMID: 30988676]
[36]
Zhu K, Miao C, Tian Y, et al. lncRNA MIR4435-2HG promoted clear cell renal cell carcinoma malignant progression via miR-513a-5p/KLF6 axis. J Cell Mol Med 2020; 24(17): 10013-26.
[http://dx.doi.org/10.1111/jcmm.15609] [PMID: 33460239]
[37]
Chen J, Song Y, Li M, et al. Comprehensive analysis of ceRNA networks reveals prognostic lncRNAs related to immune infiltration in colorectal cancer. BMC Cancer 2021; 21(1): 255.
[http://dx.doi.org/10.1186/s12885-021-07995-2] [PMID: 33750326]
[38]
Ghasemi T, Khalaj-Kondori M, Hosseinpour Feizi MA, Asadi P. Aberrant expression of lncRNAs SNHG6, TRPM2-AS1, MIR4435-2HG, and hypomethylation of TRPM2-AS1 promoter in colorectal cancer. Cell Biol Int 2021; 45(12): 2464-78.
[http://dx.doi.org/10.1002/cbin.11692] [PMID: 34431156]
[39]
Xing XL, Zhang T, Yao ZY, et al. Immune-related gene expression analysis revealed three lncRNAs as prognostic factors for colon cancer. Front Genet 2021; 12: 690053.
[http://dx.doi.org/10.3389/fgene.2021.690053] [PMID: 34306030]
[40]
Ouyang W, Ren L, Liu G, Chi X, Wei H. LncRNA MIR4435-2HG predicts poor prognosis in patients with colorectal cancer. PeerJ 2019; 7: e6683.
[http://dx.doi.org/10.7717/peerj.6683] [PMID: 30972258]
[41]
Dong X, Yang Z, Yang H, Li D, Qiu X. Long non-coding RNA MIR4435-2HG promotes colorectal cancer proliferation and metastasis through miR-206/YAP1 axis. Front Oncol 2020; 10: 160.
[http://dx.doi.org/10.3389/fonc.2020.00160] [PMID: 32154166]
[42]
Luo P, Wu S, Ji K, et al. LncRNA MIR4435-2HG mediates cisplatin resistance in HCT116 cells by regulating Nrf2 and HO-1. PLoS One 2020; 15(11): e0223035.
[http://dx.doi.org/10.1371/journal.pone.0223035] [PMID: 33232319]
[43]
Li Z, Tan H, Zhao W, et al. Integrative analysis of DNA methylation and gene expression profiles identifies MIR4435-2HG as an oncogenic lncRNA for glioma progression. Gene 2019; 715: 144012.
[http://dx.doi.org/10.1016/j.gene.2019.144012] [PMID: 31357021]
[44]
Xu H, Zhang B, Yang Y, et al. LncRNA MIR4435-2HG potentiates the proliferation and invasion of glioblastoma cells via modulating miR-1224-5p/TGFBR2 axis. J Cell Mol Med 2020; 24(11): 6362-72.
[http://dx.doi.org/10.1111/jcmm.15280] [PMID: 32319715]
[45]
Reon BJ, Takao Real Karia B, Kiran M, Dutta A. LINC00152 promotes invasion through a 3′-hairpin structure and associates with prognosis in glioblastoma. Mol Cancer Res 2018; 16(10): 1470-82.
[http://dx.doi.org/10.1158/1541-7786.MCR-18-0322] [PMID: 29991527]
[46]
Hartana CA, Rassadkina Y, Gao C, et al. Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers. J Clin Invest 2021; 131(9): 131.
[http://dx.doi.org/10.1172/JCI146136] [PMID: 33938445]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy